Browsing Tag
Opdivo
17 posts
Bristol Myers Squibb’s Opdivo receives EC approval for second-line treatment of ESCC
Bristol Myers Squibb (BMS) has achieved a significant milestone with the approval of its immunotherapy drug, Opdivo (nivolumab),…
Bristol Myers Squibb’s Opdivo and Yervoy combination approved for metastatic NSCLC in Europe
Bristol Myers Squibb (BMS) has announced a major breakthrough in cancer treatment with the European Commission’s (EC) approval…
FDA approves Opdivo and Yervoy combination for malignant pleural mesothelioma treatment
Bristol Myers Squibb (BMS) has secured approval from the US Food and Drug Administration (FDA) for a new…
FDA approves Opdivo + Yervoy for HCC previously treated with sorafenib
Bristol Myers Squibb has secured approval for the combination of Opdivo (nivolumab) 1 mg/kg and Yervoy (ipilimumab) 3…
Bristol-Myers Squibb to acquire Celgene in $74bn pharma megadeal
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately…
Bristol-Myers Squibb’s Opdivo fails to meet key endpoint in small cell lung cancer trial
Bristol-Myers Squibb’s cancer drug Opdivo (nivolumab) has failed to meet the primary endpoint in the Phase 3 CheckMate…
Bristol-Myers Squibb partners with Compugen to trial COM701 and Opdivo combination for advanced solid tumors
Bristol-Myers Squibb’s (BMS) latest clinical partnership with Israeli company Compugen is set to explore the efficacy of combining…